TrialThe journal of headache and pain2020

Impact of galcanezumab on total pain burden: findings from phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraine (EVOLVE-1, EVOLVE-2, and REGAIN trials).

Jessica Ailani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.